Targeting Thioredoxin-1 by dimethyl fumarate induces ripoptosome-mediated cell death

Constitutively active NFκB promotes survival of many cancers, especially T-cell lymphomas and leukemias by upregulating antiapoptotic proteins such as inhibitors of apoptosis (IAPs) and FLICE-like inhibitory proteins (cFLIPs). IAPs and cFLIPs negatively regulate the ripoptosome, which mediates cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Schroeder, Anne (Author) , Nicolay, Jan Peter (Author)
Format: Article (Journal)
Language:English
Published: 24 February 2017
In: Scientific reports
Year: 2017, Volume: 7
ISSN:2045-2322
DOI:10.1038/srep43168
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1038/srep43168
Verlag, kostenfrei, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324128/
Get full text
Author Notes:Anne Schroeder, Uwe Warnken, Daniel Röth, Karel D. Klika, Diana Vobis, Andrea Barnert, Fatmire Bujupi, Tina Oberacker, Martina Schnölzer, Jan P. Nicolay, Peter H. Krammer and Karsten Gülow
Description
Summary:Constitutively active NFκB promotes survival of many cancers, especially T-cell lymphomas and leukemias by upregulating antiapoptotic proteins such as inhibitors of apoptosis (IAPs) and FLICE-like inhibitory proteins (cFLIPs). IAPs and cFLIPs negatively regulate the ripoptosome, which mediates cell death in an apoptotic or necroptotic manner. Here, we demonstrate for the first time, that DMF antagonizes NFκB by suppressing Thioredoxin-1 (Trx1), a major regulator of NFκB transcriptional activity. DMF-mediated inhibition of NFκB causes ripoptosome formation via downregulation of IAPs and cFLIPs. In addition, DMF promotes mitochondrial Smac release and subsequent degradation of IAPs, further enhancing cell death in tumor cells displaying constitutive NFκB activity. Significantly, CTCL patients treated with DMF display substantial ripoptosome formation and caspase-3 cleavage in T-cells. DMF induces cell death predominantly in malignant or activated T-cells. Further, we show that malignant T-cells can die by both apoptosis and necroptosis, in contrast to resting T-cells, which are restricted to apoptosis upon DMF administration. In summary, our data provide new mechanistic insight in the regulation of cell death by targeting NFκB via Trx1 in cancer. Thus, interference with Trx1 activity is a novel approach for treatment of NFκB-dependent tumors.
Item Description:Gesehen am 06.04.2018
Physical Description:Online Resource
ISSN:2045-2322
DOI:10.1038/srep43168